WASHINGTON — Several drugmakers are expected to sign pricing agreements with the Trump administration on Friday, according to four sources familiar with the plans who were not authorized to speak publicly. This development marks a significant moment in the ongoing dialogue between the pharmaceutical industry and government officials regarding drug pricing.
The agreements are part of a broader strategy where pharmaceutical companies commit to lower drug prices and increase domestic investments in exchange for avoiding tariffs and receiving benefits like expedited drug reviews. This initiative reflects the administration’s push to control rising drug costs while simultaneously fostering domestic manufacturing.
While the specific terms of these deals have not been disclosed, their implications could reshape the landscape of pharmaceutical pricing and regulatory compliance, potentially influencing how companies approach pricing strategies and investment decisions in the future.
Start your 7-day trial and see what the database can do →
